Pediculosis (Lice)MANAGEMENT

DERMATOLOGY PRESENTATIONS · 12 SECTIONS

⚲

644 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Allergic contact dermatitis Bullous Pemphigoid Cutaneous Abscess DRESS syndrome Eczema Herpeticum Erysipelas Erythema multiforme Henoch-Schönlein purpura Herpes Zoster (Shingles)Herpetic Whitlow Hidradenitis suppurativa Paronychia Pediculosis (Lice)Pemphigus Vulgaris Pilonidal Abscess Pressure injury Psoriasis (acute flare)Psoriasis Flare Staphylococcal Scalded Skin Syndrome Stevens-Johnson Syndrome (SJS)Toxic Epidermal Necrolysis (TEN)Urticaria (acute)Warfarin-induced Skin Necrosis

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp33

Alarm features and urgent triggers

›Life-threatening complications requiring immediate action

›Fever with body lice infestation

›Suspect louse-borne systemic infection: epidemic typhus, trench fever, relapsing fever

›Immediate blood cultures and broad-spectrum antibiotics

›Rickettsia prowazekii, Bartonella quintana, Borrelia recurrentis as causative agents

›Signs of secondary bacterial infection with systemic spread

›Cellulitis with spreading erythema

›Lymphangitis

›Abscess formation requiring drainage

›Severe anemia from heavy body lice infestation

›Hemoglobin may be 2.5 mmol/l lower than matched controls

›Transfusion threshold assessment

›Epistaxis and thrombocytopenia in louse-borne relapsing fever

›Platelet count < 50 x 10^9/L as urgent threshold

›Hematology consultation

›Child protection alert

›Pubic lice in a prepubertal child

›Mandatory evaluation for sexual abuse

›Child protective services notification required

›Forensic swabs and documentation before treatment

Key clinical decision points

›Lice type determines management and urgency

›Head lice (Pediculus humanus capitis)

›Benign; not a disease vector

›Topical pediculicide first-line

›Body lice (Pediculus humanus humanus)

›Only louse type that transmits systemic disease

02History/hx64

Presenting symptoms

›Primary symptom: pruritus

›Scalp pruritus (head lice)

›May take 4 to 6 weeks to develop after initial infestation due to sensitization delay

›Nocturnal worsening

›Body and trunk pruritus (body lice)

›Waistline, lateral trunk, posterior shoulder distribution

›Pubic or perineal pruritus (pubic lice)

›May extend to eyelashes, eyebrows, axillary, or chest hair

›Associated symptoms

›Scalp excoriations

›Secondary skin infections: crusting, weeping lesions

›Sleep disturbance from nocturnal pruritus

›Posterior cervical lymphadenopathy with head lice

Exposure history

›Head lice exposure

›Head-to-head contact with infested individual

›School-aged children at sleepovers, sports, close social settings

›Not related to personal hygiene or socioeconomic status

›Shared combs, brushes, hats, or bedding (less common)

›Body lice exposure

›Homelessness or inability to change and launder clothing

›Crowded congregate settings: shelters, refugee camps, prisons

›Inability to access hygiene facilities

›Pubic lice exposure

›Sexual contact as primary route of transmission

›Shared bedding or towels (less common)

03Physical Exam/exam56

Inspection for lice and nits

›Head lice examination technique

›Fine-toothed louse comb (0.2 to 0.3 mm inter-tooth spacing)

›More sensitive and faster than visual inspection alone

›Wet combing technique: detangle first, then comb crown to tips

›Systematic combing entire head at least twice

›Examine comb after each stroke on white paper or towel

›High-yield examination areas

›Behind ears

›Nape of neck

›Live lice appearance

›1 to 3 mm in length

›Grayish-white in color

›Move quickly and avoid light

›Nit appearance

›Firmly cemented to hair shaft, cannot slide freely

›Distinguishes from dandruff and pseudonits

›Body lice examination

›Inspect clothing seams: collar, armholes, waist, pant legs

›Lice and nits found on clothing, not skin

›Skin may have fewer than 10 lice even in heavy infestation

›Skin lesion pattern

›Excoriated papules and macules at lateral trunk waistline

›Hyperpigmentation and lichenification with chronic infestation

›Central midback typically spared

›Pubic lice examination

›Nits and lice on pubic hair shaft

›Extended distribution inspection

04Differential Diagnosis/ddx48

Scalp and hair conditions

›Dandruff and seborrheic dermatitis

›ICD-10 L21.0

›Flakes loosely adherent, not cemented to hair shaft

›No lice visible on combing

›Pseudonits (hair casts)

›ICD-10 L67.8

›Cylindrical, slide freely along hair shaft with finger

›No true nits cemented to shaft

›Piedra (fungal hair shaft infection)

›Firm, hard nodules on hair shaft

›Black piedra: Piedraia hortae; white piedra: Trichosporon

›No pruritus typical

›Artifacts caught in hair

›Hairspray droplets, scabs, dirt, aphids

›Commonly misidentified as nits on cursory inspection

Dermatologic mimics

›Scabies (Sarcoptes scabiei)

›ICD-10 B86

›Burrows in web spaces, wrists, genitalia, axillae

›Worse at night; household members affected

›No lice or nits found; skin scraping shows mites

›Bedbug bites (Cimex lectularius)

›ICD-10 S00.81

›Linear or grouped papules on exposed skin

›No lice or nits; bite pattern appears after sleep

›Contact dermatitis

›ICD-10 L25.9

05Laboratory Tests/lt44

Routine testing (head and pubic lice)

›No routine laboratory tests required for uncomplicated head or pubic lice

›Clinical diagnosis by visualization

›No blood work needed unless complications suspected

›Pubic lice: STI screening

›Gonorrhea and chlamydia NAAT testing

›Urogenital, pharyngeal, and rectal sites per exposure history

›Syphilis serology

›RPR or VDRL with reflex confirmatory treponemal test

›HIV antigen/antibody combination assay

›4th generation test preferred

›Hepatitis B surface antigen and core antibody

›Baseline vaccination status review

Body lice and suspected systemic disease

›Complete blood count

›Hemoglobin for anemia assessment

›Mean hemoglobin 2.5 g/dL lower than matched controls in heavy infestation

›Transfusion threshold assessment if symptomatic

›Platelet count

›Thrombocytopenia in louse-borne relapsing fever

›Threshold < 50 x 10^9/L as critical value

›White blood cell count

›Leukocytosis with systemic bacterial infection

›Blood smear

›Febrile body louse-infested patient

›Borrelia spirochetes visible in relapsing fever during febrile episode

›Thin smear with Wright-Giemsa stain

›Inflammatory and infection markers

06Diagnostic Tests/dt40

Scoring Systems

›No validated scoring system specific to pediculosis

›Diagnosis is clinical, based on visualization of live lice

›Severity classification by type and complication

›Uncomplicated head lice: topical pediculicide and environmental decontamination

›Complicated head lice: treatment failure, widespread excoriation, secondary infection

›Body lice with systemic disease: systemic antibiotic and anti-rickettsial therapy

›Contact tracing guide

›Index patient plus all household bed-sharing contacts treated simultaneously

›Reduces reinfestation risk

›School contacts notified but mass treatment not recommended

MRI

›MRI not indicated for uncomplicated pediculosis

›No soft tissue imaging required for head, pubic, or body lice

›Clinical examination diagnostic

›No structural complications requiring MRI evaluation

›Potential role in rare complications

›Intracranial or spinal complications of louse-borne typhus encephalitis

›MRI brain if neurological signs with confirmed epidemic typhus

›CT not indicated for uncomplicated pediculosis

›No routine imaging required

›Diagnosis established by clinical examination

›No abscess or deep tissue extension expected in uncomplicated cases

›CT indications for complications

›Deep tissue abscess from superinfected excoriations

›CT soft tissue with contrast if fluctuance unclear on examination

›Splenomegaly assessment in suspected louse-borne relapsing fever

07Disposition/dispo38

Discharge criteria

›Uncomplicated head lice

›All patients suitable for outpatient management

›No hospitalization required

›Treatment initiated in clinic or ED and continued at home

›Treatment plan confirmed before discharge

›Correct application technique demonstrated or explained

›Retreatment schedule clarified: day 0 and day 9 to 10

›Environmental decontamination instructions provided

›Pubic lice

›Outpatient management appropriate

›STI screening results follow-up plan arranged

›Sexual contacts notified and referred

Admission indications

›Body lice with systemic louse-borne infection

›Louse-borne relapsing fever

›IV antibiotics required

›Jarisch-Herxheimer reaction monitoring post-treatment

›Epidemic typhus

›IV doxycycline or chloramphenicol

›Supportive care for severe illness

›Bartonella endocarditis

›Prolonged IV antibiotic therapy

›Cardiac surgery consultation if valve destruction

›Secondary bacterial infection requiring IV antibiotics

›Cellulitis non-responsive to oral therapy

›Sepsis or bacteremia

›Deep abscess requiring surgical drainage

08Treatment/t118

Head lice first-line treatment

›Permethrin 1% cream rinse (OTC)

›Application technique

›Apply to damp hair after washing with plain shampoo without conditioner

›Leave on for 10 minutes then rinse thoroughly

›Do not rewash hair for 1 to 2 days after treatment

›Retreatment

›Repeat application at day 9 to 10

›Kills newly hatched nymphs from any surviving eggs

›Age: approved for ages 2 months and older

›Safety: category B in pregnancy; preferred first-line in pregnancy

›Pyrethrins with piperonyl butoxide (OTC)

›Application technique

›Apply to dry hair; leave on 10 minutes; rinse

›Retreatment: repeat at day 9 to 10

›Age restriction: 24 months and older

›Contraindication: allergy to chrysanthemums or ragweed

Head lice second-line treatment (prescription or resistance)

›Topical ivermectin 0.5% lotion (Sklice)

›Single application to dry hair for 10 minutes then rinse

›No retreatment required in most patients

›Age: 6 months and older

›Now available OTC in many jurisdictions

›Effective against permethrin-resistant strains

›Spinosad 0.9% suspension (Natroba)

›Apply to dry hair and scalp; leave on 10 minutes; rinse

›Repeat at 7 days only if live lice persist

›Age: 6 months and older

›High efficacy including against pyrethroid-resistant lice

›Malathion 0.5% lotion (Ovide)

›Apply to dry hair; leave on 8 to 12 hours; rinse

›Repeat in 7 to 9 days if live lice remain

›Age: 6 years and older

›Flammable: avoid heat sources, hair dryers, open flames during application

›Unpleasant odor from isopropyl alcohol base

›Benzyl alcohol 5% lotion (Ulesfia)

›Apply to dry hair; leave on 10 minutes; rinse

›Repeat at day 9

›Age: 6 months and older

›Mechanism: suffocation; no neurotoxic resistance concerns

Oral treatment options

›Oral ivermectin

›Dose: 200 micrograms per kilogram body weight

›Repeat dose at 7 to 10 days

›Take with food to increase bioavailability

›Age and weight restriction

›Children 15 kg and older

›Use with caution in children under 15 kg due to blood-brain barrier immaturity

›Efficacy comparable to topical agents in resistant cases

›Class IIa recommendation for treatment-resistant head lice

Contraindicated treatments

›Lindane shampoo

›Not recommended due to neurotoxicity risk

›Seizure risk, especially in children under 10 years

›Contraindicated in pregnancy and breastfeeding

›Contraindicated in patients with extensive dermatitis

›Removed from many national formularies

›Animal-grade ivermectin products

›Never appropriate for human use

›Concentration and excipients differ from human-grade formulations

Body lice treatment

›Hygiene and clothing decontamination as primary treatment

›Wash all clothing and bedding

›Hot water cycle 60 degrees Celsius or higher

›High-heat drying cycle for at least 20 minutes

›Items not washable placed in sealed plastic bag for 2 weeks

›Lice cannot survive without human host beyond 1 to 2 weeks

›Body bathing

›Thorough bathing and hair washing

›Pharmacotherapy alone is insufficient without environmental hygiene

›Topical pediculicide for body lice if available

›Permethrin 1% cream or 5% cream to body and clothing

›Malathion 0.5% lotion as alternative

Pubic lice treatment

›First-line: permethrin 1% cream rinse or pyrethrins with piperonyl butoxide

›Apply to affected area

›Leave on 10 minutes then rinse

›Repeat at day 9 to 10

›Treat all affected hair-bearing areas including axillary hair and trunk

›Alternatives for pubic lice

›Malathion 0.5% lotion

›Apply 8 to 12 hours; repeat in 7 to 9 days if live lice persist

›Oral ivermectin 250 micrograms per kilogram

›Repeat at day 7 to 10

›Eyelash infestation (phthiriasis palpebrarum)

›Petroleum jelly (Vaseline) applied to lashes twice daily for 8 to 10 days

›Suffocates lice and nits; safe for ocular surface

›Manual removal with fine-toothed forceps

›Do NOT apply pediculicidal shampoos to eyes

Louse-borne systemic disease treatment

›Epidemic typhus (Rickettsia prowazekii)

›Doxycycline 100 mg PO or IV twice daily

›Duration: until afebrile for 48 to 72 hours (minimum 5 to 7 days)

›Class I recommendation; treatment of choice

›Chloramphenicol 500 mg IV every 6 hours as alternative

›Use only when doxycycline contraindicated

›Monitor for aplastic anemia

›Louse-borne relapsing fever (Borrelia recurrentis)

›Doxycycline 100 mg single oral dose or IV

›Single dose highly effective in louse-borne relapsing fever

›Repeat dosing not typically required

›Jarisch-Herxheimer reaction

›Occurs 2 to 8 hours after first antibiotic dose

›Rigors, high fever, hypotension, worsening illness

›Supportive management: fluids, antipyretics

›Pre-treatment with meptazinol or hydrocortisone may reduce severity

›Erythromycin 500 mg as alternative for doxycycline-contraindicated patients

›Trench fever (Bartonella quintana)

›Uncomplicated: doxycycline 200 mg PO daily for 4 weeks

›Plus gentamicin 3 mg per kg IV daily for first 14 days

›Bartonella endocarditis: prolonged therapy 6 weeks or longer

›Doxycycline 200 mg daily plus gentamicin 3 mg per kg daily for 14 days

›Cardiac surgery consultation if valve destruction

Environmental decontamination

›Head lice environmental measures

›Wash and dry bedding, clothing, and stuffed animals used in prior 48 hours

›Hot cycle: 60 degrees Celsius minimum

›High heat dry for 20 minutes

›Soak combs and brushes in hot water 60 degrees Celsius for 10 minutes

›Vacuum upholstered furniture and car seats

›Do NOT use fumigant sprays or pesticide foggers

›Not necessary; lice do not survive long off human host

›Health risk without clinical benefit

›Contact treatment guidance

›Only treat individuals with confirmed live lice

›Prophylactic treatment of uninfested household contacts not routinely recommended

09Special Populations/sp65

Pregnancy

›Safety of pediculicides in pregnancy

›Permethrin 1%: preferred first-line in pregnancy

›Category B; minimal systemic absorption

›No evidence of teratogenicity

›Pyrethrins with piperonyl butoxide: acceptable alternative

›Low systemic absorption; generally considered safe

›Topical ivermectin: limited human data

›Avoid in first trimester when possible

›Limited systemic absorption from topical route

›Oral ivermectin: not recommended in pregnancy

›Category C; some embryotoxicity in animal studies

›Avoid unless benefits clearly outweigh risks

›Malathion: use with caution; limited pregnancy data

›Lindane: absolutely contraindicated in pregnancy

›Neurotoxic and potential teratogen

›Louse-borne systemic disease in pregnancy

›High-risk condition with potential fetal compromise

›Doxycycline generally avoided in pregnancy

›After first trimester, risk-benefit discussion required

›Chloramphenicol as alternative but carries aplastic anemia risk

›Obstetric consultation required for confirmed louse-borne systemic disease

Geriatric

›Increased vulnerability in older adults

›Institutionalized patients at higher risk for head lice spread

›Nursing home, long-term care facility outbreaks require contact precautions

›Notify facility for cohorting and contact treatment

›Physical limitations affecting treatment application

›Caregiver-applied treatment may be required

›Adherence to retreatment schedule requires caregiver involvement

›Drug safety considerations in older adults

›Oral ivermectin

›Monitor for CNS side effects: dizziness, somnolence

›Renal dosing consideration if creatinine clearance impaired

›Malathion

›Anticholinesterase activity; caution in patients on cholinesterase inhibitors for dementia

›Cognitive impairment complicating self-treatment

›Caregiver education and demonstration critical

›Body lice risk in older adults

›Elder neglect and self-neglect may allow heavy infestation

›Social work and adult protective services referral as appropriate

Pediatrics

›Age-specific treatment selection

›Under 6 months: permethrin 1% only; limited data for other agents

›6 months to 2 years

›Permethrin 1% or topical ivermectin 0.5%

›Spinosad 0.9% approved from 6 months

›2 years and older: permethrin or pyrethrins first-line

›6 years and older: malathion 0.5% lotion approved

›Oral ivermectin: children 15 kg and above

›200 micrograms per kilogram; repeat at day 7 to 10

›Weight-based dosing required; do not use in children under 15 kg

›School and daycare guidance

›No-nit policies not recommended by American Academy of Pediatrics

›Evidence does not support exclusion of children with nits only

›Children with live lice may attend school until end of day then treated

›Notify school or daycare of confirmed head lice

›Child protection obligations

›Pubic lice in prepubertal child

›Mandatory referral to child protective services

›Forensic examination and STI testing required

›Severely neglected infestation with plica polonica

›Document and report to child protective services

›Assess for other neglect indicators

›Louse-borne systemic disease in children

›Doxycycline acceptable in children with serious louse-borne infections

›Short-course doxycycline now recommended by CDC and AAP for rickettsial disease regardless of age

›Risk of severe illness outweighs dental staining risk in short courses

10Background/b70

Epidemiology

›Head lice prevalence

›6 to 12 million cases per year in the United States

›Children aged 3 to 11 years most affected

›Girls affected more than boys

›Global distribution without socioeconomic or geographic predilection

›Not associated with hygiene, culture, or race

›Pyrethroid resistance widespread

›KDR (knockdown resistance) mutations prevalent in many geographic regions

›Resistance prevalence exceeds 98% in some US states

›Body lice epidemiology

›Associated with poverty, homelessness, and displacement

›Refugee camps, prisons, shelters as high-risk environments

›Endemic in areas affected by war and natural disaster

›Vector for three life-threatening systemic diseases

›Epidemic typhus, trench fever, louse-borne relapsing fever

›Millions of deaths historically in wartime epidemics

›Pubic lice prevalence

›Declining incidence in developed countries

›Associated with increased pubic hair removal practices

›Prevalence in STI clinics approximately 1 to 2%

›Sexual transmission primary route

›STI comorbidity must be assumed until excluded

Pathophysiology

›Louse biology

›Life cycle: egg (nit), nymph (3 stages), adult

›Nit incubation: 7 to 10 days

›Nymph maturation: 9 to 12 days

›Adult lifespan: 30 days on host

›Survival off host

›Head lice: up to 1 to 2 days

›Body lice: up to 4 days in clothing seams

›Explains environmental decontamination rationale

›Transmission

›Head lice: direct head-to-head contact required in most cases

›Body lice: contact with infested clothing or bedding

›Pubic lice: sexual contact in adults; non-sexual in children via close contact

›Pruritus mechanism

›Sensitization to louse saliva antigens

›Initial infestation: 4 to 6 weeks before pruritus develops

›Re-infestation: pruritus within hours due to prior sensitization

›Type I (IgE-mediated) and type IV (delayed) hypersensitivity components

›Disease vector mechanism (body lice only)

›Louse excretes infected feces while feeding

›Rickettsiae, Bartonella, Borrelia deposited in feces on skin

›Entry through abraded skin during scratching

›Head and pubic lice do NOT transmit these organisms

Therapeutic Considerations

›Resistance management

›Pyrethroid resistance (permethrin, pyrethrins)

›KDR mutations in voltage-gated sodium channels

›Clinical failure: live lice present 24 hours after permethrin treatment despite correct technique

›Switch to non-pyrethroid agent: spinosad, topical ivermectin, or malathion

›No reported resistance to oral ivermectin or benzyl alcohol

›Resistance testing not clinically available; management based on treatment failure

›Retreatment rationale

›First treatment kills live lice but not all nits

›Nit hatching over 7 to 10 days produces new nymphs

›Second treatment at day 9 to 10 kills newly hatched nymphs before maturity

›Topical ivermectin and spinosad may not require second treatment due to sustained ovicidal effect

›Environmental decontamination principles

›Lice require human blood meal every 1 to 2 days

›Environmental treatment (fumigation) not beneficial or necessary

›Focus on direct host treatment and fomite decontamination

›Excessive environmental response (discarding toys, sealing rooms) not evidence-based

›Increases family burden without clinical benefit

›Treatment failure evaluation

›Confirm correct application technique before declaring failure

›Conditioner use prior to treatment reduces permethrin binding

›Insufficient contact time

›Confirm live lice versus dead lice or empty nits

›Nits may remain on hair shaft after successful treatment

›Re-infestation from untreated contact must be excluded

11Patient Discharge Instructions/pdi41

copy discharge instructions

›Head lice home treatment instructions

›Use the pediculicide exactly as prescribed or as directed on the OTC label

›Apply to affected hair as instructed: usually 10 minutes contact time

›Rinse thoroughly after the contact time is complete

›Repeat treatment at day 9 or 10 (count treatment day as day 1)

›Do not repeat treatment sooner than day 7

›Do not use conditioner or combination shampoo-conditioner on treatment day

›Conditioner blocks medication from working

›Nit combing

›Use a fine-toothed louse comb after each treatment

›Wet hair and comb from scalp to tip section by section

›Clean comb between strokes on a white paper towel

›Continue daily nit combing to check for live lice until clear

›Household and environmental care

›Wash all bedding, hats, scarves, and recently worn clothing

›Hot water 60 degrees Celsius or higher; high-heat dry for 20 minutes

›Soak combs and brushes in hot water for 10 minutes

›Vacuum upholstered furniture and car seats

›Do not use bug sprays or fumigant sprays in the home

›Contact notification and treatment

›Check all household members and close contacts for live lice

›Only treat individuals who are confirmed to have live lice

›Inform school, daycare, or close contacts of exposure

›No-nit policies are not supported by medical evidence

›Children can return to school once treatment has been applied

›Return to ER warning signs

›Fever, chills, or severe headache with body lice infestation

12References/r27

Guidelines and key sources

›Society guidelines

›American Academy of Pediatrics (AAP) Clinical Report on Head Lice 2022

›Treatment algorithm, resistance management, no-nit policy recommendation

›CDC Parasites: Lice guidance

›Head lice, body lice, pubic lice management and epidemiology

›World Health Organization: louse-borne disease vector control guidelines

›Body lice and systemic disease management in humanitarian settings

›British Association for Sexual Health and HIV (BASHH): pubic lice guideline

›STI co-testing, contact tracing, treatment algorithms

Evidence sources

›Key evidence

›Devore and Schutze; AAP 2022 head lice clinical report

›Permethrin and pyrethrin resistance prevalence; topical ivermectin and spinosad evidence summary

›Raoult and Roux; louse-borne disease review

›Epidemic typhus, trench fever, relapsing fever: pathogenesis, clinical features, treatment

›Brouqui et al; body lice as disease vector in homeless populations

›Bartonella quintana endocarditis and trench fever in homeless cohorts

›Frankowski and Bocchini; clinical management of pediculosis

›Diagnosis, resistance, retreatment schedules

Coding standards

›Diagnostic codes

›ICD-10 B85.0: pediculosis due to Pediculus humanus capitis (head louse)

›ICD-10 B85.1: pediculosis due to Pediculus humanus corporis (body louse)

›ICD-10 B85.2: pediculosis unspecified

›ICD-10 B85.3: phthiriasis (pubic lice)

›ICD-10 B85.4: mixed pediculosis and phthiriasis

›ICD-10 A75.0: epidemic louse-borne typhus fever

Learn More: Pediculosis (Lice)→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.